Ascendis Health, whose shares have slumped on concerns about its debt levels and weak organic growth, says it is considering selling the two remaining businesses in its biosciences division after it offloaded three companies in that unit.

The sale of Afrikelp, Efekto and Marltons, announced in May, is now complete after receiving approval from competition authorities, Ascendis said on Wednesday. The businesses were sold to a consortium comprising RMB Ventures Seven, Nedbank Private Equity and some managers at Ascendis’s biosciences division. ..

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now